<DOC>
	<DOCNO>NCT00660179</DOCNO>
	<brief_summary>The AC-055-302/SERAPHIN study event-driven Phase III study , compare two different dos macitentan ( ACT-064992 ) ( 3 10 mg ) v placebo patient symptomatic PAH . The main study objective demonstrate macitentan ( ACT-064992 ) prolongs time first morbidity mortality event , evaluate benefit/risk profile macitentan ( ACT-064992 ) treatment patient symptomatic PAH .</brief_summary>
	<brief_title>Study Macitentan ( ACT-064992 ) Morbidity Mortality Patients With Symptomatic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Signed informed consent prior initiation study mandate procedure . 2 . Patients symptomatic pulmonary arterial hypertension ( PAH ) modify World Health Organization ( WHO ) functional class II IV . 3 . Patients follow type pulmonary arterial hypertension ( PAH ) belong group 1.1 1.3 Venice classification : Idiopathic ( IPAH ) ; Familial ( FPAH ) ; Related : Collagen vascular disease ; Simple , congenital systemictopulmonary shunt least 1 year post surgical repair ; Human immunodeficiency virus ( HIV ) infection ; Drugs toxins . 4 . PAH diagnosis confirm hemodynamic evaluation perform prior randomization show follow : Mean pulmonary artery pressure ( mPAP ) &gt; 25 mmHg rest ; Pulmonary capillary wedge pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) &lt; 15 mmHg ; Pulmonary vascular resistance ( PVR ) rest &gt; = 320 dyn√ósec/cm^5 . 5 . 6minute walk distance ( 6MWD ) &gt; = 50 m. 6 . Men woman &gt; 12 year age ( woman childbearing potential must negative pretreatment serum pregnancy test must use reliable method contraception ) . 1 . PAH associate portal hypertension , thyroid disorder , glycogen storage disease , Gaucher '' disease , hereditary hemorrhagic telangiectasia , hemoglobinopathy , myeloproliferative disorder splenectomy . 2 . PAH associate non correct simple congenital systemictopulmonary shunt , combine complex systemictopulmonary shunt , correct non correct . 3 . PAH associate significant venous capillary involvement ( PCWP &gt; 15 mmHg ) , know pulmonary venoocclusive disease , pulmonary capillary hemangiomatosis . 4 . Persistent pulmonary hypertension newborn . 5 . Pulmonary Hypertension belong group 2 5 Venice classification . 6 . Moderate severe obstructive lung disease : forced expiratory volume 1 second/forced vital capacity ( FEV1/FVC ) &lt; 70 % FEV1 &lt; 65 % predict value bronchodilator administration . 7 . Moderate severe restrictive lung disease : total lung capacity ( TLC ) &lt; 60 % predict value . 8 . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. 9 . Estimated creatinine clearance &lt; 30 mL/min 10 . Serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal . 11 . Hemoglobin &lt; 75 % low limit normal range . 12 . Systolic blood pressure &lt; 100 mmHg . 13 . Acute chronic physical impairment ( dyspnea ) , limit ability comply study requirement . 14 . Pregnant breastfeeding . 15 . Known concomitant lifethreatening disease life expectancy &lt; 12 month . 16 . Body weight &lt; 40 kg . 17 . Any condition prevents compliance protocol adherence therapy . 18 . Recently start ( &lt; 8 week prior randomization ) plan cardiopulmonary rehabilitation program base exercise . 19 . Treatment endothelin receptor antagonist ( ERAs ) within 3 month prior randomization . 20 . Systemic treatment within 4 week prior randomization cyclosporine A tacrolimus , everolimus , sirolimus ( calcineurin mammalian target rapamycin ( mTOR ) inhibitor ) . 21 . Treatment cytochrome P3A ( CYP3A ) inducer within 4 week prior randomization 22 . Known hypersensitivity drug class study drug , excipients . 23 . Planned treatment , treatment , another investigational drug within 1 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>pulmonary arterial hypertension SERAPHIN</keyword>
</DOC>